Enzo Biochem reports results in the second quarter of 2025 – Tradingview News

Farmingdale, NY, March 17, 2025 (Globe Newswire) – Enzo Biochem, Inc. Enz (“Enzo” or the “company”) announced the financial results for the second quarter in the second quarter, which ended on January 31, 2025, with the succession improved sales, gross margin and operating profit / loss achieving a sequential improvement.

Financial highlights

• The company's gross margin percentage in the second quarter of 52% rose one after the other of 37% in the first quarter of 2025 and rose from 49% in the second quarter of the previous year. These improvements were promoted by changes in the income, the conclusion of cost efficiency and the mix of products sold.
• The Enzo Life Sciences Products segment, which no longer achieved in operation and corporate effort in the second quarter of $ 25 in the second quarter in the second quarter of 25 USD in the second quarter of $ 25 and an improvement of $ 0.2 million worth 1.5 USD in the second quarter of the previous year. These improvements were promoted by changes in the income, the conclusion of cost efficiency and the mix of products sold.
• The loss of operating losses for the first half of the financial year25 for the continued company of the company improved by $ 2.4 million. Due to the cost of the cost, the company lowered sales costs by 14%. In addition, the expenses in SG&A and F&E took back 22% and 27%. The product launches are continued despite the reduction in F&E.
• The company's turnover in the second quarter of USD $ 6.2 million rose by $ 1.1 million in succession. This is an improvement of 18%. The quarterly period of the annual supply period decreased by 14% primarily from the time of the fulfillment of large order and the slowdown of the market in the USA.
• Enzo ended the second quarter with a total of cash and cash equivalents of $ 40.3 million. The board of directors and management continue to focus on maintaining cash.
• The product life cycle maintenance continues with increasing number of SkU starts. Enzo increased the product launch to strengthen the basic business in the first half of the financial year and to double the number of new products compared to the previous year.

Recent events

• As already announced, the company and the plaintiffs submitted a class-wide comparison contract for the cyber incident in April 2023 and an unrestricted application for provisional approval at the court. The Court granted the application and set a final hearing on June 10, 2025. The comparative value of $ 7.5 million was expired in our financial financial statements last year, and a first payment was made after January 31, 2025 of USD 0.8 million.
• We continue to examine all strategic alternatives to maximize the value for the shareholders of the company, including without restriction, improving the market position and profitability of our services on the market and the improvement of our assessment. We can pursue our goals through organic growth and strategic initiatives. In addition, we will continue to check information on potential acquisitions or joint ventures and provide information about possible dispositions of assets or business borders, including a potential sale of the company, from time to time.
• On February 21, 2025, the company submitted a plan to heal market capitalization, equity and average closure exchange defects and to return to compliance with the continued listing standards of the NYSE. The plan takes into account all available alternatives to healing the defects identified by the NYSE, which are checked by the NYSE. The ordinary shares are still listed and act in the NYSE, subject to continuous compliance with the other continued listing standards of the NYSE and the acceptance of this plan.

About Enzo Biochem

Enzo Biochem, Inc. has been working as a bio -scientific company for over 45 years. Enzo's primary business is carried out today by its life sciences Enzo Life Sciences, which focuses on the identification and detection technologies from DNA to the entire cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genome probes, assays, biochemical and protein. The company's proprietary products and technologies play a central role in areas of translational research and drug development, including cell biology, genomics, assays, immunohistochemistry and chemistry for small molecules. The company monetizes its technology mainly through the sale of our global sales network and licensing. You can find more information at Enzo.com or follow Enzo Biochem on X and LinkedIn.

Predicted statements

With the exception of historical information, the matters discussed in this publication can be viewed as “future -oriented” statements in the sense of section 27a of the Securities Act from 1933 in the changed version and section 21e of the Securities Exchange Act from 1934 in the changed version. These statements include explanations of intentions, conviction or current expectations of the company and its administration, including those who are dependent on the cash flow, gross margins, the income and expenditure in connection with a number of factors outside the control of the company, including, including, among other things, the markets of the company, the costs of the goods sold, other expenditure, state regulation, cables and general business. See risk factors in the company's form 10 k form for the financial year that ended on July 31, 2024. Investors are pointed out that such future -oriented statements are not guarantees for future performance and include a number of risks and uncertainties that could significantly influence the actual results. The company rejects all obligations to update a future -oriented declaration due to developments after the date of this publication.

Enzo Biochem contacts

For Enzo Biochem:

Patricia Eckert, Chief Financial Officer

Enzo biochem

631-755-5500

peckert@enzo.com

Use of non -GAAP financial measures by Enzo

The non-GAAP financial measures contained in this press release (including, without restriction, adapted net desire, EBITDA and adjusted EBITDA) are not GAAP measures for the financial performance or liquidity of the company and should not be an alternative to the net result (loss) as a measure of financial performance or cash flow as measurements of liquidity or other performance measurement or another service created with GAAP. A reconciliation of such non-GAAP measures is included in the presentation of the company's financial results for the ending quarter of January 31, 2025 and is also available in the “Investor Relations” of the company's website (https://www.enzo.com).

The company is of the opinion that the presentation of these non-GAAP measures provides investors with useful additional information, since they provide information available with the agreement on which the management evaluates the financial performance of the company. The company manages its business based on its operational cash flows. It refers to EBITDA as the main indicator for performance and refers to the adapted EBITDA in order to further exclude the elements of a non -lived nature. It can be expected that one or more excluded points will take place in future periods in future periods, although the recognized amounts can vary significantly from period to period. You will be asked to evaluate any adjustment to determine a non-GAAP financial measure, and the reasons for the reasons for the supplementary analysis. Our presentation of these measures should not be interpreted as a conclusion that our future results are not influenced by unusual or not reorganized elements.

We refer you to the tables connected to this press release, which contains voting tables of the GAAP netto lust for adapted net loss and GAAP -Nettoverlust for EBITDA and adapted EBITDA.